Crispr Therapeutics shares tumble after significant earnings miss
LONDON - Hargreave Hale AIM VCT PLC ("the Company") has announced the allotment of 95,512 new Ordinary Shares on Friday, following an offer to raise up to £20 million as detailed in their prospectus dated October 9, 2024, and the supplementary prospectus from December 20, 2024. The shares were issued at a price of 37.01 pence each, based on the net asset value as of May 30, 2025, and adjusted for the costs of the offer.
The new shares are expected to be admitted to the closed-ended investment funds category of the Official List of the Financial Conduct Authority and to commence trading on the London Stock Exchange’s main market around June 13, 2025. Upon issuance, these shares will rank equally with the existing Ordinary Shares in the company.
This issuance brings the total number of Ordinary Shares in the company to 371,982,460, with each share carrying one vote, setting the total voting rights at the same number. Shareholders may use this figure as the denominator for notifications required under the Disclosure Guidance and Transparency Rules.
The Company has stated that the new Ordinary Shares will be issued in registered form and may be held in uncertificated form, with definitive documents of title expected to be dispatched within 15 business days of allotment. Additionally, the shares will be eligible for settlement through CREST from the date of admission.
The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.